KDR and colorectal carcinoma: 25). In normal homoeostatic processes angiogenesis occurs transiently; however, in the cancer setting it can become permanently switched on. This is associated with poor prognosis and therefore inhibitors of molecules involved in vessel formation are currently utilised for CRC in combination with chemotherapy. For example, bevacizumab is a biologic which inhibits tumour angiogenesis through blockade of vascular endothelial growth factor receptor (VEGFR). Bevacizumab is currently used clinically in the metastatic CRC setting in combination with adjuvant chemotherapy (Ref. 55).